Ahmet Barış DURUKAN, Nevriye SALMAN, Elif DURUKAN, Hasan Alper GÜNDÜZ, Cem YORGANCIOĞLU, Halil İbrahim UÇAR, Murat TAVLAŞOĞLU, Fatih Tanzer SERTER

An evaluation of 6% hydroxyethyl starch 130/0.4 use in fluid therapy following coronary artery surgery

Amaç: Bu çalışmada koroner arter baypas cerrahisi yapılan hastalarda %6 hidroksietil nişasta 130/0.4’ün etkileri, sıklıkla kullanılan dengeli bir elektrolit solüsyonu ile karşılaştırıldı. Çalışma planı: Koroner arter baypas cerrahisi yapılan 157 hasta iki gruba randomize edildi. İlk gruba %6 hidroksietil nişasta 130/0.4, ikinci gruba ise sıklıkla kullanılmakta olan dengeli bir elektrolit solüsyonu verildi. Her iki solüsyonun da ameliyat sonrası sonuçlar üzerine olan etkileri araştırıldı.Bulgular: Yüze altı hidroksietil nişasta 130/0.4 ameliyat sonrası kan kaybı ve kullanılan kan ve kan ürünü miktarını artırmadı (p>0.05). Renal ve pulmoner fonksiyonlar üzerine olumsuz etkisi saptanmadı. Entübasyon zamanı, yoğun bakım kalış süresi ve ameliyat sonrası hastane kalış süresi açısından gruplar arasında fark görülmedi (p>0.05). Hidroksietil nişastanın ameliyat sonrası atriyal fibrilasyon oluşumu üzerine herhangi bir etkisi saptanmadı (p>0.05).Sonuç: Yüze altı hidroksietil nişasta 130/0.4 koroner baypas cerrahisi sonrası sıvı tedavisinde güvenli olarak kullanılabilir.

Koroner arter cerrahisi sonrası sıvı tedavisinde %6 hidroksietil nişasta 130/0.4 kullanımının değerlendirilmesi

Background: This study aims to compare the effects of 6% hydroxyethylstarch 130/0.4 with a commonly used balanced electrolyte solution in patients undergoing coronary artery bypass surgery. Methods: One hundred and fifty seven patients who underwent coronary artery bypass surgery were randomized into two groups. The first group received 6% hydroxyethyl starch 130/0.4, while the second group received a commonly used balanced electrolyte solution. The effects of both solutions on postoperative outcomes were studied.Results: Six percent hydroxyethyl starch 130/0.4 did not increase postoperative blood loss and the amount of blood and blood products (p>0.05). No adverse effect was observed on renal and pulmonary functions. Intubation time, intensive care unit stay and postoperative duration of hospital stay did not differ between the groups (p>0.05). Hydroxyethyl starch had no effect on the occurrence of postoperative atrial fibrillation (p>0.05).Conclusion: Six percent hyroxyethyl starch 130/0.4 may be considered safe in fluid therapy following coronary bypass surgery.

PDF

___

1) Larmann J, Theilmeier G. Inflammatory response to cardiac surgery: cardiopulmonary bypass versus noncardiopulmonary bypass surgery. Best Pract Res Clin Anaesthesiol 2004;18:425-38.
2) Warren OJ, Smith AJ, Alexiou C, Rogers PL, Jawad N, Vincent C, et al. The inflammatory response to cardiopulmonary bypass: part 1--mechanisms of pathogenesis. J Cardiothorac Vasc Anesth 2009;23:223-31. doi: 10.1053/j.jvca.2008.08.007.
3) Verheij J, van Lingen A, Beishuizen A, Christiaans HM, de Jong JR, Girbes AR, et al. Cardiac response is greater for colloid than saline fluid loading after cardiac or vascular surgery. Intensive Care Med 2006;32:1030-8.
4) Lange M, Ertmer C, Van Aken H, Westphal M. Intravascular volume therapy with colloids in cardiac surgery. J Cardiothorac Vasc Anesth 2011;25:847-55. doi: 10.1053/j. jvca.2010.06.005.
5) James MF. Pro: hydroxyethyl starch is preferable to albumin in the perioperative management of cardiac patients. J Cardiothorac Vasc Anesth 2008;22:482-4. doi: 10.1053/j. jvca.2008.02.017.
6) Nuttall GA, Oliver WC. Con: use of colloids in cardiac surgery. J Cardiothorac Vasc Anesth 2007;21:457-9.
7) Ernest D, Belzberg AS, Dodek PM. Distribution of normal saline and 5% albumin infusions in cardiac surgical patients. Crit Care Med 2001;29:2299-302.
8) Damar E, Aksun M, Girgin S, Göktoğan T, Yılmaz E, Aran G ve ark. Koroner arter baypas greft ameliyatlarında pompa prime solüsyonu olarak Ringer ve Ringer solüsyonuna eklenmiş %6’lık hidroksietil nişasta (130/0.4-HES) kullanımının hemodinamik, metabolik, renal ve hemostatik etkilerinin karşılaştırılması. Turk Gogus Kalp Dama 2012;20:22-31.
9) Joachim Boldt. Available from: http://en.wikipedia.org/wiki/ Joachim_Boldt. html. [Accessed: June 09, 2012]
10) Wise J. Boldt: the great pretender. BMJ 2013;346:f1738.
11) Westphal M, James MF, Kozek-Langenecker S, Stocker R, Guidet B, Van Aken H. Hydroxyethyl starches: different products--different effects. Anesthesiology 2009;111:187-202. doi: 10.1097/ALN.0b013e3181a7ec82.
12) Jungheinrich C, Neff TA. Pharmacokinetics of hydroxyethyl starch. Clin Pharmacokinet 2005;44:681-99.
13) Jungheinrich C. The starch family: Are they all equal? Pharmacokinetics and pharmacodynamics of hydroxyethyl starches. Transfus Altern Transfus Med 2007;9:152-63.
14) Sirvinskas E, Sneider E, Svagzdiene M, Vaskelyte J, Raliene L, Marchertiene I, et al. Hypertonic hydroxyethyl starch solution for hypovolaemia correction following heart surgery. Perfusion 2007;22:121-7.
15) Emmert MY, Salzberg SP, Theusinger OM, Felix C, Plass A, Hoerstrup SP, et al. How good patient blood management leads to excellent outcomes in Jehovah's witness patients undergoing cardiac surgery. Interact Cardiovasc Thorac Surg 2011;12:183-8. doi: 10.1510/icvts.2010.242552.
16) Raja SG, Akhtar S, Shahbaz Y, Masood A. In cardiac surgery patients does Voluven(R) impair coagulation less than other colloids? Interact Cardiovasc Thorac Surg 2011;12:1022-7. doi: 10.1510/icvts.2010.263939.
17) Ooi JS, Ramzisham AR, Zamrin MD. Is 6% hydroxyethyl starch 130/0.4 safe in coronary artery bypass graft surgery? Asian Cardiovasc Thorac Ann 2009;17:368-72. doi:10.1177/0218492309338101.
18) Schramko A, Suojaranta-Ylinen R, Kuitunen A, Raivio P, Kukkonen S, Niemi T. Hydroxyethylstarch and gelatin solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Br J Anaesth 2010;104:691-7.
19) Navickis RJ, Haynes GR, Wilkes MM. Effect of hydroxyethyl starch on bleeding after cardiopulmonary bypass: a metaanalysis of randomized trials. J Thorac Cardiovasc Surg 2012;144:223-30. doi: 10.1016/j.jtcvs.2012.04.009.
20) Wilkes MM, Navickis RJ, Sibbald WJ. Albumin versus hydroxyethyl starch in cardiopulmonary bypass surgery: a meta-analysis of postoperative bleeding. Ann Thorac Surg 2001;72:527-33.
21) Base EM, Standl T, Lassnigg A, Skhirtladze K, Jungheinrich C, Gayko D, et al. Efficacy and safety of hydroxyethyl starch 6% 130/0.4 in a balanced electrolyte solution (Volulyte) during cardiac surgery. J Cardiothorac Vasc Anesth 2011;25:407-14. doi: 10.1053/j.jvca.2010.12.005.
22) Wang P, Li Y, Li J. Protective roles of hydroxyethyl starch 130/0.4 in intestinal inflammatory response and oxidative stress after hemorrhagic shock and resuscitation in rats. Inflammation 2009;32:71-82. doi: 10.1007/s10753-009-9105-7.
23) Villareal RP, Hariharan R, Liu BC, Kar B, Lee VV, Elayda M, et al. Postoperative atrial fibrillation and mortality after coronary artery bypass surgery. J Am Coll Cardiol 2004;43:742-8.
24) Shirzad M, Karimi A, Tazik M, Aramin H, Hossein Ahmadi S, Davoodi S, et al. Determinants of postoperative atrial fibrillation and associated resource utilization in cardiac surgery. Rev Esp Cardiol 2010;63:1054-60.
25) Harutjunyan L, Holz C, Rieger A, Menzel M, Grond S, Soukup J. Efficiency of 7.2% hypertonic saline hydroxyethyl starch 200/0.5 versus mannitol 15% in the treatment of increased intracranial pressure in neurosurgical patients - a randomized clinical trial. [ISRCTN62699180]. Crit Care 2005;9:R530-40.
26) Demirok M, Aşkın D, Emin İ, Güleç Ç, Ada E, Çiçek AE. Düşük molekül ağırlıklı hidroksietil nişastanın açık kalp ameliyatlarında kullanımı. Turk Gogus Kalp Dama 2009;17:162-6.